Mlejnek P
Cells. 2023; 12(5).
PMID: 36899844
PMC: 10000661.
DOI: 10.3390/cells12050709.
Ruzickova E, Skoupa N, Dolezel P, Smith D, Mlejnek P
Biomolecules. 2019; 9(11).
PMID: 31683643
PMC: 6921012.
DOI: 10.3390/biom9110675.
Swietach P, Hulikova A, Patiar S, Vaughan-Jones R, Harris A
PLoS One. 2012; 7(4):e35949.
PMID: 22563426
PMC: 3338554.
DOI: 10.1371/journal.pone.0035949.
Gerweck L, Kozin S, Stocks S
Br J Cancer. 1999; 79(5-6):838-42.
PMID: 10070878
PMC: 2362684.
DOI: 10.1038/sj.bjc.6690134.
DeGregorio M, Carrera C, Klock J, WILBUR J
Cancer Chemother Pharmacol. 1982; 10(1):29-32.
PMID: 6961971
DOI: 10.1007/BF00257233.
Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.
Baurain R, Robert J, AUBEL-SADRON G
Cancer Chemother Pharmacol. 1982; 9(1):45-8.
PMID: 6958392
DOI: 10.1007/BF00296761.
Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells.
Seeber S, LOTH H
Blut. 1981; 42(6):355-65.
PMID: 6941824
DOI: 10.1007/BF00996898.
Cytofluorescence localization of adriamycin in resistant colon cancer cells.
Chauffert B, Martin F, Caignard A, Jeannin J, Leclerc A
Cancer Chemother Pharmacol. 1984; 13(1):14-8.
PMID: 6733840
DOI: 10.1007/BF00401439.
Uptake, metabolism, and cytotoxicity of doxorubicin in human Ewing's sarcoma and rhabdomyosarcoma cells.
DeGregorio M, Lui G, Macher B, WILBUR J
Cancer Chemother Pharmacol. 1984; 12(1):59-63.
PMID: 6690077
DOI: 10.1007/BF00255912.
Comparative studies of the uptake of daunorubicin in sensitive and resistant P388 cell lines by flow cytometry and biochemical extraction procedures.
McGown A, Ward T, Fox B
Cancer Chemother Pharmacol. 1983; 11(2):113-6.
PMID: 6627597
DOI: 10.1007/BF00254258.
Characteristics and effect of antiinflammatory drugs on adriamycin-induced inflammation in the mouse paw.
Siegel D, Giri S, Scheinholtz R, Schwartz L
Inflammation. 1980; 4(2):233-47.
PMID: 6446523
DOI: 10.1007/BF00914168.
Cellular pharmacokinetics of daunorubicin: uptake by leukaemic cells in vivo and fate.
Trillet V, Lakhal M, LANG J, Timour Chah Q, Fiere D, FAUCON G
Eur J Clin Pharmacol. 1985; 29(1):127-9.
PMID: 4054202
DOI: 10.1007/BF00547382.
Lysosomal alterations in heart and liver of mice treated with doxorubicin.
Gebbia N, Leto G, Gagliano M, Tumminello F, Rausa L
Cancer Chemother Pharmacol. 1985; 15(1):26-30.
PMID: 4006046
DOI: 10.1007/BF00257289.
Hepatic metabolism of doxorubicin in mice and rats.
Vrignaud P, Robert J
Eur J Drug Metab Pharmacokinet. 1986; 11(2):101-5.
PMID: 3770010
DOI: 10.1007/BF03189834.
Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites.
Wassermann K, Steiness E
Cancer Chemother Pharmacol. 1986; 17(3):241-6.
PMID: 3742710
DOI: 10.1007/BF00256692.
Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages.
Renard C, Vanderhaeghe H, Claes P, Zenebergh A, Tulkens P
Antimicrob Agents Chemother. 1987; 31(3):410-6.
PMID: 3579258
PMC: 174742.
DOI: 10.1128/AAC.31.3.410.
Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation.
Panneerselvam M, Bredehorst R, Vogel C
Proc Natl Acad Sci U S A. 1986; 83(23):9144-8.
PMID: 3466179
PMC: 387091.
DOI: 10.1073/pnas.83.23.9144.
Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.
Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C
Cancer Chemother Pharmacol. 1990; 25(4):252-6.
PMID: 2295112
DOI: 10.1007/BF00684881.
Adriamycin uptake and metabolism in organotypic culture of A549 human adenocarcinoma cells according to the exposure time.
Chevillard S, Vielh P, Bastian G, Coppey J
J Cancer Res Clin Oncol. 1990; 116(6):633-8.
PMID: 2254382
DOI: 10.1007/BF01637086.
Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat.
Wedge S, Duncan R, Kopeckova P
Br J Cancer. 1991; 63(4):546-9.
PMID: 1827030
PMC: 1972366.
DOI: 10.1038/bjc.1991.128.
